Dyfyniad APA

Preiss, D., Herrington, W., & Haynes, R. (2022). Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: The EMPA-KIDNEY trial. American Heart Association.

Dyfyniad Arddull Chicago

Preiss, D., W. Herrington, and R. Haynes. Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial. American Heart Association, 2022.

Dyfyniad MLA

Preiss, D., et al. Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial. American Heart Association, 2022.

Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.